Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis

Fig. 5

Forest plots of common adverse events, grade ≥ 3 adverse events and cardiotoxicity events in controlled studies: combination of pertuzumab with HER2 inhibitors versus HER2-targeted therapies without pertuzumab for patients with HER2+ breast cancer. HER2 = human epidermal growth factor receptor 2, OR = odds ratio

Back to article page